The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.

Kamson, David O; Grossman, Stuart A

Kamson, David O; Grossman, Stuart A.

Kamson DO; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
Grossman SA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

JAMA Oncol ; 7(5): 675-676, 2021 05 01.

Article in English | MEDLINE | ID: covidwho-1039141

Subject(s)

Antineoplastic Agents, Alkylating/therapeutic use; Brain Neoplasms/therapy; Chemoradiotherapy; Chemotherapy, Adjuvant/methods; Glioblastoma/therapy; Temozolomide/therapeutic use; Brain Neoplasms/genetics; COVID-19; DNA Methylation; DNA Modification Methylases/genetics; DNA Repair Enzymes/genetics; Glioblastoma/genetics; Humans; Isocitrate Dehydrogenase/genetics; SARS-CoV-2; Survival Rate; Tumor Suppressor Proteins/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Brain Neoplasms / Chemotherapy, Adjuvant / Glioblastoma / Antineoplastic Agents, Alkylating / Chemoradiotherapy / Temozolomide Type of study: Prognostic study Limits: Humans Language: English Journal: JAMA Oncol Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google